IFNA17 and neoplasm: From the launch of the first tumor immunotherapy drug (IFN-α) to the current immune checkpoint inhibitors (PD-1/PD-L1, CLTA-4) (15), CAR-T cell therapy (16), tumor vaccines (17), oncolytic viruses (18), and other new drugs, these drugs have shown good therapeutic effects and hence are approved for tumor immunotherapy.